Key Highlights

  • Revenue Growth: IDEXX recorded $1.214 billion in Q3 2026 revenues, up 10% on both a reported and organic basis.
  • EPS Expansion: Earnings per diluted share reached $4.01, up 18% as reported and 22% on a comparable basis year over year.
  • Guidance Raised: Full-year 2026 Revenue guidance increased to $4.741–$4.767 billion, up $32 million at the midpoint from prior guidance.
  • Instrument Momentum: More than 1,900 IDEXX inVue Dx analyzers were placed during the quarter, bringing the installed base to nearly 11,000.

IDEXX Laboratories, Inc.(NASDAQ:IDXX) reported third quarter 2026 results that exceeded expectations across multiple metrics, lifting its full-year outlook and reflecting a period of consistent execution in the companion animal diagnostics market.

Q3 2026 Financial Performance

Total revenues for the third quarter reached $1.214 billion, representing 10% growth on both a reported and organic basis. The Companion Animal Group, which forms the core of IDEXX's business, grew at the same 10% rate, with CAG Diagnostics Recurring Revenue — the highest-margin and most strategically significant segment — advancing 11% both as reported and on an organic basis.

Within CAG Diagnostics recurring revenue, the international segment outperformed, posting 13% to 14% organic growth. U.S. CAG Diagnostics recurring revenue grew 10% organically, which the company described as outpacing overall sector growth levels. IDEXX VetLab consumables, which depend on the installed base of in-clinic analyzers, grew 14% to 15% organically, reflecting net new customer additions, utilization expansion from recent product launches, and net price gains. Reference laboratory services grew 10% as reported and organically.

Earnings per diluted share came in at $4.01, an 18% increase as reported and 22% growth on a comparable basis. Gross Margin expanded 110 basis points as reported to 62.9%, supported by Volume leverage, productivity initiatives, and price realization. Operating Margin reached 33.1%, up 100 basis points as reported and 60 basis points on a comparable basis, even as the company absorbed costs related to the CoVet Acquisition completed during the quarter.

Innovation Driving the Installed Base

The IDEXX inVue Dx analyzer, which combines cytology with fine-needle aspiration capability, saw over 1,900 placements during the quarter, bringing the cumulative installed base to nearly 11,000 instruments. The company also highlighted IDEXX Cancer Dx evolving into a multi-cancer detection panel, broadening what veterinary practices can identify in a single diagnostic workflow.

The acquisition of CoVet, an artificial intelligence clinical assistant designed to support veterinary team productivity and diagnostics utilization, was completed during the quarter and is now incorporated into the guidance update. CoVet added approximately $5 million to the raised revenue guidance at midpoint. President and CEO Mike Erickson described the strategic logic as creating more value for customers by helping veterinary teams detect disease earlier and work more efficiently — a positioning that connects software Investment to Downstream diagnostic volume.

IDEXX will highlight its next point-of-care analyzer, IDEXX MultiCue Dx, at an investor session during VMX in January 2027 in Orlando. That event is likely to be watched closely for details on the next instrument cycle's capabilities and potential installed base dynamics.

Risks

IDEXX's guidance update lowered its full-year reported operating margin outlook to 32.1%–32.3% from a prior range of 32.3%–32.5%, primarily reflecting acquisition-related costs. While the margin adjustment is modest, it signals that integration spending and Transaction Costs from CoVet will affect the near-term margin trajectory. The company is also absorbing the financial impact of foreign currency headwinds, with an estimated 0.7% negative impact on revenue growth and roughly $0.25 of EPS impact for the year.

The broader companion animal sector continues to face macroeconomic sensitivity, with pet healthcare spending subject to consumer discretionary pressures. Any softening in veterinary visit volumes or practice capacity constraints could affect diagnostic testing demand, though IDEXX has historically shown some insulation from short-term sector fluctuations through its recurring revenue model.

What to Watch Next

The raised full-year EPS guidance range of $14.96–$15.16 represents projected comparable growth of 15%–16%, a meaningful step up from the prior midpoint. Investors will focus on whether CAG Diagnostics recurring revenue sustains the double-digit organic growth rate through the fourth quarter, and whether the inVue Dx installed base continues to expand at a pace that supports consumables revenue in 2027.

The IDEXX MultiCue Dx preview at VMX in January 2027 will be the next major product narrative to track, as new analyzer launches have historically been catalysts for accelerated instrument placements and eventual consumable pull-through.

Sector Context

Veterinary diagnostics is a specialized segment of the broader healthcare diagnostics market, characterized by recurring revenue models tied to instrument placements and long customer relationships. IDEXX holds a dominant position in in-clinic diagnostics for companion animals and has increasingly expanded into software and AI tools that embed more deeply into the veterinary practice workflow. The company's growth trajectory in Q3 2026 aligns with a multi-year pattern of above-market gains driven by product innovation and geographic expansion, particularly internationally where penetration of diagnostic testing remains lower than in the United States.